By Connor Hart
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer.
The drug, Opdualag, didn't meet its primary endpoint of recurrence-free survival when used as an additional treatment for patients with completely resected stage III-IV melanoma.
Vice President Jeffrey Walch, Opdualag global program lead, said Thursday that patients whose tumors are completely resected, or surgically removed, may not have enough antitumor T cells left for the drug to have its maximal effect.
"Opdualag remains a standard of care in the first-line treatment of unresectable or metastatic melanoma," he said, "and we continue to explore its potential across tumor types, including in non-small cell lung cancer."
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
February 13, 2025 17:42 ET (22:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.